Navigation Links
ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
Date:2/9/2009

- Conference Call at 10:00 A.M. Today to Discuss Results -

EXTON, Pa., Feb. 9 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that its Phase 3 trial evaluating maribavir used as prophylaxis in allogeneic stem cell, or bone marrow, transplant (SCT) patients did not achieve its primary endpoint. In the primary analysis, there was no statistically significant difference between maribavir and placebo in reducing the rate of CMV disease. In addition, the study failed to meet its key secondary endpoints. Maribavir was generally well tolerated in this clinical study.

"We are extremely disappointed by the outcome of this pivotal study," said Vincent J. Milano, ViroPharma's president and chief executive officer. "We just received these data and there are far more questions than answers; we still have a significant amount of work to do to fully understand this outcome and its impact on the overall program. Our disappointment is no doubt shared by physicians and transplant patients, who must today contend with CMV disease."

The primary endpoint of this Phase 3 study was the incidence of CMV disease, confirmed by an independent endpoint committee, within 6 months post-transplant. The incidence of CMV disease within 6 months was 4.4 percent for maribavir compared to 4.8 percent for placebo (P=0.79). The first of four key secondary endpoints was the rate of initiation of anti-CMV treatment within 6 months, which was 37.9 percent for maribavir compared to 40.5 percent for placebo (P=0.49). In addition, the incidence of graft-versus-host disease, mortality and CMV disease-free survival was comparable between the groups.

Conference Call and Webcast

ViroPharma is hosting a live teleconference and webcast with se
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
2. ViroPharma Provides Update on Vancocin(R)
3. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
4. ViroPharma To Present At The 20th Annual Piper Jaffray Healthcare Conference
5. ViroPharma to Discuss Commercialization and Launch of Cinryze(TM) on November 5, 2008
6. ViroPharma Incorporated Reports Third Quarter 2008 Financial Results
7. ViroPharma to Release 2008 Second Quarter Financial Results on July 30, 2008
8. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
9. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
10. Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma
11. ViroPharma Provides Update on Vancocin(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... July 01, 2015 , ... The 28th annual Charity Horse Show hosted by ... 2015, at 6 p.m. in Pugh Bourne Park, 343 Oakfield Road. The event will ... zoo, an Elvis impersonator, a silent auction and concessions. , Horses and riders from ...
(Date:7/1/2015)... ... ... Convoy of Hope will partner with local businesses, churches, government ... 1, at Spring Lake Park High School. , During the celebration, Convoy of Hope ... goods and services including free food, health services, family portraits, job services, a carnival ...
(Date:7/1/2015)... KY (PRWEB) , ... July 01, 2015 , ... ... Care Transformation Task Force, contributing to newly released white paper: “Pro-actively Identifying the ... paper was published July 1st and is available at: http://www.hcttf.org/resouces-tools . , ...
(Date:7/1/2015)... ... July 01, 2015 , ... Franklin University, one of the leading educators ... has been named Dean of the College of Health & Public Administration ... and support the vision and mission of Franklin University via curriculum planning, course scheduling, ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... summer sale. Customers purchasing two or more Bunion Booties directly from their ... , Bunion Bootie temporarily corrects misaligned toes and its ultra thin properties allow ...
Breaking Medicine News(10 mins):Health News:Convoy of Hope Hosts Community Event in the Twin Cities 2Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 2Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 3Health News:Franklin University Appoints Dean of College of Health & Public Administration 2Health News:Bunion Bootie, the #1 Non-Surgical Treatment for Bunion Pain, Announces Their Big Summer Sale 2
... Gerontological Society of America (GSA) the nation,s ... has chosen Alan Jette, PhD, of Boston University ... of Aging Persons Award. This distinguished honor is ... of rehabilitation. The awardee,s work may be in any ...
... be used to determine whether a lung cancer patient ... published in the August issue of the Journal ... the International Association for the Study of Lung Cancer ... been found to respond well to crizotinib, an ALK ...
... aero-digestive tract cancers (UADT), especially those of the oral cavity, ... as it has been shown repeatedly that heavy drinkers, in ... alcohol use and cigarette smoking is the key factor in ... distinguished group of scientists from the International Agency for Research ...
... sulfide is a foul-smelling gas with an odor resembling that ... is generally associated with decaying vegetation, sewers and noxious industrial ... it also plays a critical role in protecting blood vessels ... from the University of Texas Medical Branch at Galveston. ...
... (HealthDay News) -- Heart attack survivors who live in ... neighborhoods, a new study finds. Regular exercise after ... of survival, the Israeli researchers noted. In the ... more than 10 years to assess their levels of ...
... over 75 are likely to have at least one abnormal liver ... likely to die from cancer and 17 times more likely to ... of Alimentary Pharmacology and Therapeutics . UK researchers studied ... to an in-depth health assessment. Patients were drawn at random from ...
Cached Medicine News:Health News:Jette to receive GSA's 2011 Excellence in Rehabilitation of Aging Persons Award 2Health News:The effects of smoking and alcohol use on risk of upper aero-digestive cancers 2Health News:Scientists show 'swamp gas' protects blood vessels from complications of diabetes 2Health News:Abnormal liver tests associated with increased death rates in people over 75 2Health News:Abnormal liver tests associated with increased death rates in people over 75 3
(Date:7/1/2015)... 2015  Genoa has acquired West Bend Assisted Living ... pharmacy location with a proven track record for excellent ... settings, and those involved in their care. Both companies ... delivering true value to their customers. ... of pharmacy services dedicated to the behavioral health community ...
(Date:7/1/2015)... July 1, 2015 Egalet Corporation (Nasdaq: ... pharmaceutical company focused on developing, manufacturing and marketing ... Radie , president and chief executive officer, is ... He will provide an update on Egalet,s marketed ... Nasal Spray, approved product OXAYDO ™ (oxycodone ...
(Date:7/1/2015)... FRANCISCO , July 1, 2015 ... market) is expected to reach USD 49,119.2 million by ... Research, Inc. Monitoring services is expected to remain the ... of USD 1,227.5 million in 2012, and an estimated ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , Browse ...
Breaking Medicine Technology:Genoa, a QoL Healthcare Company Acquires West Bend Assisted Living Pharmacy 2Egalet to Present at Upcoming Conferences This Summer 2Egalet to Present at Upcoming Conferences This Summer 3mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 2mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 3mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 4mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 5
... announced today that it has licensed technology from Yale University ... in the January issue of the journal Cell Cycle ... associated with breast cancer risk, such mutations in BRCA1 ... The research identified microRNA disrupting variants in and around ...
... N.J., Feb. 24, 2011 University Radiology Group, ... teleradiology services, is working with MedInformatix Inc. to ... to achieve Stage 1 meaningful use ... Reinvestment Act (ARRA) for Health Information Technology. ...
Cached Medicine Technology:Mira Dx Licenses Triple Negative Breast Cancer Risk Variant from Yale University 2University Radiology Group Works With MedInformatix to Meet Stage 1 Meaningful Use Qualifications 2University Radiology Group Works With MedInformatix to Meet Stage 1 Meaningful Use Qualifications 3
Porous foundation 440 series....
Exactech's AcuMatch C-Series (cemented femoral stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
The Biopro optima stem is manufactured from cobalt chrome and is available in a Non-Porous coat option....
The cemented hip joint prosthesis system....
Medicine Products: